| 
			 The three physicians stand out in the Medicare data released last 
			month because they conducted three to four times more drug tests per 
			patient than any other provider in the country. In fact, they 
			ordered so many individual tests, their patients averaged one every 
			other day. 
 A surge in prescription drug abuse among older Americans has been 
			accompanied by a big increase in urine and blood tests nationwide. 
			Part of an effort to detect that abuse, the tests generate millions 
			of dollars for providers. Medicare, the government insurance system 
			for the disabled and people 65 years and older, is footing the bill.
 
 Medicare administrators declined to comment on the doctors' bills or 
			to say whether they were investigating. But experts in laboratory 
			billing said the high frequency of tests was extremely unusual and 
			underscored the need for Medicare to improve oversight of 
			potentially lucrative drug tests to guard against billing for 
			unnecessary procedures.
 
 "Those numbers are ridiculously high," said Dr Stuart Gitlow, acting 
			president of the American Society of Addiction Medicine. "There is 
			no medical indication I can think of that would require such 
			frequency of testing. I can't come up with a scenario at all."
 
			
			 
 Two of the doctors work together in New London, Connecticut. The 
			third doctor works in Ellington, about 60 miles away. Two of the 
			three, contacted by Reuters, denied any wrongdoing, with one saying 
			he was simply following Medicare's billing rules as he understood 
			them. The third declined to comment.
 
 Each of the doctors requested only the most expensive and 
			comprehensive drug test, for as much as $94, rather than the simpler 
			$19 one. This was done to improve the accuracy of the results, one 
			said.
 
 "SPIGOT OF MONEY"
 
 Medicare paid medical providers $457 million in 2012 for 16 million 
			tests to detect everything from prescription narcotics to cocaine 
			and heroin, according to the Reuters analysis.
 
 "In some parts of the country every doctor and his cousin is hanging 
			out a shingle to do (addiction) treatment. There’s a tailor-made 
			opportunity for ordering a profusion of tests instead of one," said 
			Bill Mahon, former executive director of the National Health Care 
			Anti-Fraud Association.
 
 "It's like turning on a spigot of money," he said.
 
 Urine and blood tests are potential areas of fraud and abuse because 
			guidelines for drug testing are vague, leaving the frequency of 
			testing to the discretion of the provider. Unlike private insurance 
			companies, which sometimes dispute charges and pay providers only 
			when they have vetted a claim, Medicare almost always pays first and 
			asks questions later.
 
 There is often a legitimate need for such drug tests, to determine 
			whether an addict has relapsed or to ensure that patients prescribed 
			painkillers are taking them rather than selling them.
 
 In 2011, the average number of older Americans misusing or dependent 
			on prescription pain relievers grew to about 336,000, up from 
			132,000 a decade earlier, according to the Substance Abuse and 
			Mental Health Services Administration.
 
 Urine drug testing first showed up on the radar screen of Medicare 
			investigators in 2011. Since then the Office of the Inspector 
			General of Health and Human Services, which oversees Medicare, has 
			settled three cases in which it charged providers whose billings for 
			drug tests were deemed excessive.
 
 
			 
			When Medicare administrators released the payment data for 880,000 
			healthcare providers last month, officials said they hoped outside 
			experts would comb through it for possible waste, fraud, and abuse.
 
 DECIPHERING BILLS
 
 Addiction psychiatrist Erum Shahab of Ellington conducted 8,518 drug 
			tests for 43 Medicare patients in 2012, the Reuters analysis found. 
			That's an average of 198 per patient and the most of any Medicare 
			provider in 2012.
 
 Shahab declined to comment on her billing.
 
 Medicare reimbursed her billing number $207,046 for these tests, 
			which detect multiple classes of drugs. Ninety-five percent of her 
			Medicare revenue came from the tests.
 
 New London-based Dr Bassam Awwa, who also specializes in treating 
			addiction, conducted 13,260 drug tests for 90 patients in 2012, or 
			147 per patient. That's about three per week for every patient. 
			Medicare paid his billing number $983,894.
 
 [to top of second column]
 | 
            
			 
			Dr Ammar Traboulsi, who shares an office with Awwa, was paid for 
			2,142 drug tests on 12 patients in 2012, or an average 178 tests per 
			patient. Medicare paid his billing number $159,107.
 Among the thousands of providers who charged Medicare for drug 
			tests, the next highest number of tests per patient in 2012 was 50. 
			Excluding the three Connecticut doctors, the median number per 
			patient nationwide was 1.3.
 "We would never do that many drug 
			screenings here, even in our intensive outpatient treatment center," 
			said Dr Elizabeth Howell, the director of the Addiction Psychiatry 
			Fellowship Training Program at the University of Utah 
			Neuropsychiatric Institute, when Reuters read her the numbers for 
			the three Connecticut doctors.
 "There's a big question mark in my mind about what they're doing," 
			she said.
 
 It is not possible to tell from the Medicare data how many providers 
			are fraudulently or wastefully billing for drug tests. For instance, 
			some physicians may be ordering tests on the vast majority of their 
			patients, even those with no history of abuse.
 
 Recent court cases, however, hint at the extent of the problem.
 
 In February, SelfRefind, a chain of addiction treatment centers in 
			Kentucky, agreed to pay $15.75 million to settle allegations that 
			they billed Medicare and Medicaid for drug tests that were medically 
			unnecessary and many times more expensive than other suitable 
			alternative tests, the Department of Justice said in a statement.
 
 HOW TO BILL
 
 Doctors Awwa and Traboulsi run a program in which patients addicted 
			to opioids are given Suboxone, a drug made by Britain's Reckitt 
			Benckiser <RB.L> as a safer substitute, much as heroin addicts are 
			weaned off that drug through methadone.
 
 Awwa said the payment numbers for his practice were correct, but 
			misleading. He conducts drug tests only once a week for patients in 
			the Suboxone program, not the three times per week the Medicare data 
			suggest.
 
			 
 But he billed Medicare separately for each drug he tested. Rather 
			than charging Medicare once to test a patient for ecstasy, ketamine 
			and bath salts, for instance, Awwa charged the program three times.
 
 "This is the way we were told to bill," he said. "We are not doing 
			them artificially to generate revenue."
 
 Traboulsi, in a separate interview, offered similar explanations.
 
 Medicare billing rules effective Jan. 1, 2011, however, prohibit 
			providers from charging for each drug tested.
 
 "If you did one drug, if you did 50 drugs, it should have been times 
			one," said Melissa Scott, a laboratory billing consultant.
 
 Awwa said he believed the guideline was effective as of 2013 and 
			since then has charged Medicare for only one test per patient visit. 
			Medicare has not responded to Reuters' requests for Awwa's 2013 and 
			2011 billing data.
 
 Medicare uses an automated procedure to halt payments to providers 
			who bill multiple times for the same drug test, according to Rob 
			DeConti, assistant Inspector General of Legal affairs at the Office 
			of the Inspector General. But providers can skirt the automated 
			denials by changing the way they submit their bills.
 
 Awwa said Medicare audited him and found nothing wrong with his 
			laboratory billing practices. Medicare said it does not confirm or 
			deny whether it has investigated any provider.
 
 (Reporting By M.B. Pell and Sharon Begley, editing by Michele 
			Gershberg and Ross Colvin)
 
			[© 2014 Thomson Reuters. All rights 
				reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed. 
			
			 |